Pelthos Therapeutics Inc. — Form 10-Q/A
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q/A
— Neutral
significance 8/100
What the filing says
This is an amended Form 10-Q/A for the quarter ended March 31, 2026, filed August 13, 2026. The document contains only standard Sarbanes-Oxley Section 302 and 906 certifications by CEO Scott Plesha and CFO John M. Gay, attesting to the accuracy of financial statements and effectiveness of disclosure controls. No specific financial results, amendments to prior disclosures, or business changes are detailed in the provided exhibits.
Why this rating
Amendment flag signals prior error correction; certification-only exhibits reveal no material substantive detail. Cannot assess magnitude without main filing body.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.